Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
pulmonary fibrosis
Biotech
Vicore's IPF drug improves lung function in phase 2 win
Having stacked all its chips on the idiopathic pulmonary fibrosis treatment buloxibutid, Vicore Pharma’s bet may be paying off.
James Waldron
May 20, 2024 2:00am
BMS charts 2nd pulmonary fibrosis win with LPA1 antagonist
Sep 11, 2023 10:05am
BMS' pulmonary fibrosis drug reduces lung function decline
May 22, 2023 1:05pm
Immunotherapies targeting 2 peptides blast fibrosis in mice
Sep 16, 2022 3:20pm
Insilico nets $255M to put AI-made drugs through clinical trials
Jun 22, 2021 9:45am
Genentech taps Imbio to develop AI for scanning lung diseases
Oct 8, 2020 10:25am
